Emily Moore, APRN
Psychiatric/Mental Health · Tulsa, OKNPI 1730436668
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 579 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 579 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$958
- Corium, LLC$955
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$839
- Alkermes, Inc.$820
- Supernus Pharmaceuticals, Inc.$354
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,74799%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 129 | $1,484 |
| Johnson & Johnson | 70 | $958 |
| Corium, LLC | 46 | $955 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $839 |
| Alkermes, Inc. | 53 | $820 |
| Supernus Pharmaceuticals, Inc. | 19 | $354 |
| Neurocrine Biosciences, Inc. | 21 | $350 |
| Axsome Therapeutics, Inc. | 14 | $321 |
| Vanda Pharmaceuticals Inc. | 19 | $308 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $258 |
| Otsuka America Pharmaceutical, Inc. | 13 | $247 |
| Teva Pharmaceuticals USA, Inc. | 16 | $246 |
| Bausch Health US, LLC | 11 | $224 |
| Ironshore Pharmaceuticals Inc. | 14 | $215 |
| E.r. Squibb & Sons, L.L.C. | 17 | $203 |
| Eisai Inc. | 16 | $203 |
| Lundbeck LLC | 10 | $184 |
| Jazz Pharmaceuticals Inc. | 11 | $171 |
| Sunovion Pharmaceuticals Inc. | 9 | $143 |
| Avanir Pharmaceuticals, Inc. | 3 | $67 |
| Avion Pharmaceuticals | 2 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| Sage Therapeutics, LLC | 2 | $34 |
| Adlon Therapeutics L.p. | 2 | $29 |
| Almatica Pharma LLC | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Harmony Biosciences LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
| Merck | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$121
How this compares
$8,801 in reported general payments places this provider in the 90th percentile of 231 psychiatric/mental health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 14 | $47,954 |
| RexultiBrexpiprazole | 17 | $23,413 |
| Escitalopram Oxalate | 111 | $1,262 |
| Trazodone Hcl | 56 | $1,107 |
| Duloxetine Hcl | 60 | $940 |
| Sertraline Hcl | 40 | $936 |
| Risperidone | 64 | $843 |
| Aripiprazole | 34 | $696 |
| Hydroxyzine Hcl | 36 | $574 |
| Mirtazapine | 50 | $550 |
| Propranolol Hcl | 31 | $505 |
| Quetiapine Fumarate | 19 | $498 |
| Bupropion XlBupropion Hcl | 22 | $487 |
| Guanfacine Hcl ErGuanfacine Hcl | 11 | $480 |
| Buspirone Hcl | 39 | $412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada | $820 | $47,95414 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $247 | $23,41317 claims |
| Almatica Pharma LLCSertraline Hcl | $28 | $93640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Tulsa
- Fernanda CooleyTulsa$16K
- Pramila TraxlerTulsa$12K
- Sabrina ConleyTulsa$10K
- la Maria FolksTulsa$10K
- Caroline LeithnerTulsa$7K
- John StanfordTulsa$5K
- Rebekah MackeyTulsa$5K
- Kari MurphyTulsa$5K
- Jordan GillinghamTulsa$5K
- Jennifer AycockTulsa$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.